| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $33.6M | -16.3% |
| SG&A Expense | $15.2M | -30.5% |
| Operating Income | -$50.0M | +24.8% |
| Pre-tax Income | -$50.2M | +20.6% |
| Net Income | -$50.2M | +20.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $2.6M | -73.6% |
| Short-term Investments | $7.2M | -81.6% |
| Current Assets | $11.6M | -77.6% |
| Total Assets | $19.6M | -71.1% |
| Current Liabilities | $3.9M | -49.1% |
| Total Liabilities | $9.7M | -53.7% |
| Stockholders' Equity | $9.8M | -78.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$45.1M | +9.8% |
| Capital Expenditures | $132K | -26.7% |
| Investing Cash Flow | $32.1M | +368.4% |
| Financing Cash Flow | $5.8M | — |
| Free Cash Flow | -$45.2M | +9.8% |